Your browser doesn't support javascript.
loading
Risks of alopecia areata in long COVID: Binational population-based cohort studies from South Korea and Japan.
Kyung, Seoyeon; Son, Yejun; Kim, Minji; Kang, Jiseung; Smith, Lee; Lee, Hayeon; Yon, Dong Keon.
Afiliación
  • Kyung S; Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Son Y; Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
  • Kim M; Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Kang J; Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Smith L; Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Lee H; Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
  • Yon DK; Harvard Medical School, Division of Sleep Medicine, Boston, Massachusetts, USA.
J Med Virol ; 96(5): e29668, 2024 May.
Article en En | MEDLINE | ID: mdl-38757870
ABSTRACT
Previous studies have proposed alopecia areata (AA) as a potential outcome of COVID-19 infection among autoimmune diseases, yet the findings might be inconclusive and difficult to generalize due to limited sample sizes and evidence levels. Thus, we aimed to investigate in detail the long-term risk of AA following SARS-CoV-2 infection based on large, binational, general population-based cohort studies. Our study investigated the long-term AA risk after SARS-CoV-2 infection by analyzing bi-national, claim-based cohorts in South Korea and Japan a Korean nationwide cohort (K-COV-N cohort; discovery cohort; total n = 10 027 506) and a Japanese claims-based cohort (JMDC cohort; validation cohort; total n = 12 218 680). AA was identified based on the international classification of diseases 10th revision code (L63) requiring at least three claims within 1 year. After exposure-driven propensity score matching, SARS-CoV-2 infection was associated with an increased risk of incident AA (aHR, 1.66; 95% CI, 1.38-1.99). This increased risk was observed and persisted for up to 6 months. A similar pattern was observed in the validation cohort. As modifiable factors, severe COVID-19 increased the risk of AA, whereas receiving two or more doses of the COVID-19 vaccine before infection decreased the risk of AA. Through a bi-national cohort study in South Korea and Japan, SARS-CoV-2 infection was associated with an elevated risk for incident AA in the aspect of long COVID.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alopecia Areata / COVID-19 Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: J Med Virol Año: 2024 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alopecia Areata / COVID-19 Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: J Med Virol Año: 2024 Tipo del documento: Article País de afiliación: Corea del Sur Pais de publicación: Estados Unidos